TABLE OF CONTENTS
1 INTRODUCTION 59
1.1 OBJECTIVES OF THE STUDY 59
1.2 MARKET DEFINITION 59
1.3 OVERVIEW 59
1.4 CURRENCY AND PRICING 61
1.5 LIMITATIONS 61
1.6 MARKETS COVERED 61
2 MARKET SEGMENTATION 67
2.1 MARKETS COVERED 67
2.2 GEOGRAPHICAL SCOPE 68
2.3 YEARS CONSIDERED FOR THE STUDY 69
2.4 DBMR TRIPOD DATA VALIDATION MODEL 70
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.6 MULTIVARIATE MODELLING 74
2.7 PRODUCTS LIFELINE CURVE 74
2.8 DBMR MARKET POSITION GRID 75
2.9 SECONDARY SOURCES 77
2.10 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHT 81
4.1 PESTEL ANALYSIS 82
4.2 PORTER'S FIVE FORCES MODEL 83
4.3 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET ANALYSIS 84
4.4 PATENT ANALYSIS 85
5 PIPELINE ANALYSIS 87
6 EPIDEMIOLOGY 88
7 INDUSTRY INSIGHTS 89
7.1 DEMOGRAPHIC TRENDS 89
7.2 KEY PRICING STRATEGIES 91
7.3 KEY PATIENT ENROLLMENT STRATEGIES 92
8 REGULATORY SCENARIO FOR MEDICAL FOOD 94
9 MARKET OVERVIEW 97
9.1 DRIVERS 99
9.1.1 RISING INCIDENCES OF INBORN ERRORS OF METABOLISM (IEM) 99
9.1.2 RISING PREFERENCE FOR DIETARY SUPPLEMENTS OVER ENZYME REPLACEMENT THERAPY (ERT) 100
9.1.3 INCREASE IN THE NUMBER OF NEW-BORN SCREENING PROCEDURES 101
9.1.4 INCREASING SPENDING ON MEDICAL FOOD PRODUCTS 102
9.2 RESTRAINTS 103
9.2.1 HIGH COST OF MEDICAL FOODS 103
9.2.2 STRINGENT REGULATIONS FOR MEDICAL FOODS 104
9.3 OPPORTUNITIES 105
9.3.1 GOVERNMENT INITIATIVES AND PROGRAMS FOR CREATING AWARENESS ABOUT INBORN ERRORS OF METABOLISM 105
9.3.2 INCREASING COLLABORATIONS AND PARTNERSHIPS IN THE MARKET 107
9.3.3 EXPANSION OF MEDICAL FOODS IN EMERGING MARKETS 107
9.4 CHALLENGES 108
9.4.1 POOR ACCESSIBILITY OF MEDICAL FOODS 108
9.4.2 ALTERNATIVE TREATMENT APPROACHES FOR INBORN ERRORS OF METABOLISM 109
10 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PRODUCTS 110
10.1 OVERVIEW 111
10.2 AMINO ACID 114
10.2.1 AMINO ACID MIXTURES 115
10.2.1.1 PHENYLADE 116
10.2.1.1.1 DRINK MIX 116
10.2.1.1.2 GMP MIX-IN 116
10.2.1.1.3 GMP READY 116
10.2.1.1.4 OTHERS 116
10.2.1.2 PERIFLEX 116
10.2.1.3 LOPHLEX 117
10.2.1.4 PHLEXY 117
10.2.1.5 COOLER 117
10.2.1.6 ANAMIX 117
10.2.1.7 LYSINE-FREE, LOW TRYPTOPHAN 117
10.2.1.8 GLUTARADE ESSENTIAL GA-1 117
10.2.1.9 GLUTARADE GA-1 AMINO ACID BLEND 117
10.2.1.10 GLYTACTIN WITH GMP 117
10.2.1.11 ESSENTIAL AMINO ACID MIX 117
10.2.1.12 LIQUIGEN 117
10.2.1.13 MSUD GEL 118
10.2.1.14 OTHERS 118
10.2.2 SINGLE AMINO ACID 118
10.2.2.1 L-ARGININE 118
10.2.2.2 L-ISOLEUCINE 118
10.2.2.3 L-TYROSINE 119
10.2.2.4 L-LEUCINE 119
10.2.2.5 GLYCINE 119
10.2.2.6 L-ASPARTIC ACID 119
10.2.2.7 L-CITRULLINE 119
10.2.2.8 OTHERS 119
10.3 LOW PROTEIN FOOD 119
10.3.1 LOW-PROTEIN BAKING MIXES AND FLOUR SUBSTITUTES, SUCH AS RICE FLOUR OR POTATO FLOUR 121
10.3.2 LOW-PROTEIN ENERGY BARS AND SNACKS 121
10.3.3 LOW-PROTEIN CEREALS AND BREAKFAST FOOD 121
10.3.4 LOW-PROTEIN MILK SUBSTITUTES, SUCH AS RICE MILK OR ALMOND MILK 121
10.3.5 LOW-PROTEIN BREAD, PASTA, AND OTHER GRAIN-BASED PRODUCTS 121
10.3.6 OTHERS 121
10.4 GLYTACTIN WITH GMP AMINO ACID-MODIFIED INFANT FORMULA WITH IRON 121
10.4.1 BY FLAVOUR 122
10.4.1.1 VANILLA 122
10.4.1.2 BERRY 122
10.4.1.3 ORANGE 123
10.4.1.4 PLAIN 123
10.4.1.5 OTHERS 123
10.4.2 BY USAGE 123
10.4.2.1 READY TO DRINK 123
10.4.2.2 NEED DILUTION/PREPARATION 123
10.5 LOW-CALCIUM/VITAMIN D-FREE INFANT FORMULA WITH IRON 124
10.5.1 NO CALCIUM OR VITAMIN D 125
10.5.2 LOW CALCIUM, NO VITAMIN D 125
10.5.3 OTHERS 125
10.6 OTHERS 125
11 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISEASES 127
11.1 OVERVIEW 128
11.2 PHENYLKETONURIA (PKU) 131
11.2.1 PHENYLADE 132
11.2.2 PERIFLEX 132
11.2.3 LOPHLEX 132
11.2.4 OTHERS 132
11.3 TYROSINEMIA TYPES I AND II 132
11.4 MAPLE SYRUP URINE DISEASE (MSUD) 133
11.4.1 ANAMIX 134
11.4.2 COOLER 134
11.4.3 MSUD GEL 134
11.4.4 AMINO ACID BLEND 134
11.4.5 MAXMUM 134
11.4.6 OTHERS 134
11.5 HOMOCYSTINURIA 135
11.6 GLUTARIC ACIDEMIA TYPE I 135
11.7 UREA CYCLE DISORDERS 136
11.7.1 ORNITHINE TRANSCARBAMYLASE DEFICIENCY (OTC) 137
11.7.2 CARBAMYL PHOSPHATE SYNTHETASE DEFICIENCY (CPS) 137
11.7.3 CITRULLINAEMIA 137
11.7.4 N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY (NAGS) 137
11.7.5 ARGINASE DEFICIENCY (AG) 138
11.7.6 ARGININOSUCCINIC ACIDURIA (ASA) 138
11.7.7 OTHERS 138
11.8 METHYLMALONIC ACIDEMIA 138
11.9 ISOVALERIC ACIDEMIA 139
11.10 ORGANIC ACIDURIAS 140
11.11 RENAL DISEASE 140
11.12 PROPIONIC ACIDEMIA 141
11.13 DISORDERS OF LEUCINE METABOLISM 142
11.14 OTHERS 143
12 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY AGE GROUP 144
12.1 OVERVIEW 145
12.2 INFANTS 148
12.3 WEANING 148
12.4 ADOLESCENT 149
12.5 ADULTS 150
13 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY FORMS 151
13.1 OVERVIEW 152
13.2 POWDER 155
13.3 LIQUID 155
13.4 TABLETS 156
13.5 GELS 157
13.6 OTHERS 158
14 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY PACKAGING 159
14.1 OVERVIEW 160
14.2 CAN 163
14.3 PACKETS 163
14.4 BOTTLE 164
14.5 JAR 165
14.6 OTHERS 165
15 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY DISTRIBUTION CHANNEL 167
15.1 OVERVIEW 168
15.2 HOSPITAL PHARMACY 171
15.3 RETAIL PHARMACY 171
15.4 DRUG STORES 172
15.5 ONLINE PHARMACY 173
15.6 OTHERS 173
16 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, BY REGION 175
16.1 ASIA-PACIFIC 176
16.1.1 CHINA 191
16.1.2 JAPAN 201
16.1.3 INDIA 210
16.1.4 AUSTRALIA 220
16.1.5 SOUTH KOREA 230
16.1.6 THAILAND 239
16.1.7 SINGAPORE 249
16.1.8 INDONESIA 258
16.1.9 MALAYSIA 267
16.1.10 NEW ZEALAND 276
16.1.11 VIETNAM 284
16.1.12 PHILIPPINES 292
16.1.13 TAIWAN 302
16.1.14 REST OF ASIA-PACIFIC 311
17 ASIA PACIFIC MEDICAL FOODS FOR INBORN ERRORS OF METABOLISM MARKET, COMPANY LANDSCAPE 312
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 312
18 SWOT ANALYSIS 313
19 COMPANY PROFILE 314
19.1 ABBOTT 314
19.1.1 COMPANY SNAPSHOT 314
19.1.2 REVENUE ANALYSIS 314
19.1.3 COMPANY SHARE ANALYSIS 315
19.1.4 PRODUCT PORTFOLIO 315
19.1.5 RECENT DEVELOPMENT 316
19.2 NESTL HEALTH SCIENCE (A SUBSIDIARY OF NESTL) 317
19.2.1 COMPANY SNAPSHOT 317
19.2.2 COMPANY SHARE ANALYSIS 317
19.2.3 PRODUCT PORTFOLIO 318
19.2.4 RECENT DEVELOPMENT 318
19.3 AJINOMOTO CAMBROOKE, INC. (A SUBSIDIARY OF AJINOMOTO CO., INC.) 319
19.3.1 COMPANY SNAPSHOT 319
19.3.2 COMPANY SHARE ANALYSIS 319
19.3.3 PRODUCT PORTFOLIO 320
19.3.4 RECENT DEVELOPMENTS 320
19.4 MEAD JOHNSON & COMPANY, LLC. (A SUBSIDIARY OF RECKITT BENCKISER GROUP PLC.) 321
19.4.1 COMPANY SNAPSHOT 321
19.4.2 COMPANY SHARE ANALYSIS 321
19.4.3 PRODUCT PORTFOLIO 322
19.4.4 RECENT DEVELOPMENT 322
19.5 NUTRICIA (A SUBSIDIARY OF DANONE) 323
19.5.1 COMPANY SNAPSHOT 323
19.5.2 COMPANY SHARE ANALYSIS 323
19.5.3 PRODUCT PORTFOLIO 324
19.5.4 RECENT DEVELOPMENT 325
19.6 APR 326
19.6.1 COMPANY SNAPSHOT 326
19.6.2 PRODUCT PORTFOLIO 326
19.6.3 RECENT DEVELOPMENT 326
19.7 B.BRAUN SE 327
19.7.1 COMPANY SNAPSHOT 327
19.7.2 PRODUCT PORTFOLIO 327
19.7.3 RECENT DEVELOPMENT 327
19.8 BAXTER 328
19.8.1 COMPANY SNAPSHOT 328
19.8.2 REVENUE ANALYSIS 328
19.8.3 PRODUCT PORTFOLIO 329
19.8.4 RECENT DEVELOPMENT 329
19.9 DR. SCHR AG / SPA 330
19.9.1 COMPANY SNAPSHOT 330
19.9.2 PRODUCT PORTFOLIO 330
19.9.3 RECENT DEVELOPMENT 331
19.10 EBM MEDICAL 332
19.10.1 COMPANY SNAPSHOT 332
19.10.2 PRODUCT PORTFOLIO 332
19.10.3 RECENT DEVELOPMENT 332
19.11 ENER-G FOODS, INC. 333
19.11.1 COMPANY SNAPSHOT 333
19.11.2 PRODUCT PORTFOLIO 333
19.11.3 RECENT DEVELOPMENT 333
19.12 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA) 334
19.12.1 COMPANY SNAPSHOT 334
19.12.2 PRODUCT PORTFOLIO 334
19.12.3 RECENT DEVELOPMENT 334
19.13 GALEN LIMITED 335
19.13.1 COMPANY SNAPSHOT 335
19.13.2 PRODUCT PORTFOLIO 335
19.13.3 RECENT DEVELOPMENTS 335
19.14 HEXAGONNUTRITION LTD. 336
19.14.1 COMPANY SNAPSHOT 336
19.14.2 PRODUCT PORTFOLIO 336
19.14.3 RECENT DEVELOPMENT 336
19.15 KATE FARMS 337
19.15.1 COMPANY SNAPSHOT 337
19.15.2 PRODUCT PORTFOLIO 337
19.15.3 RECENT DEVELOPMENTS 338
19.16 MEIJI HOLDINGS CO., LTD. 339
19.16.1 COMPANY SNAPSHOT 339
19.16.2 REVENUE ANALYSIS 339
19.16.3 PRODUCT PORTFOLIO 340
19.16.4 RECENT DEVELOPMENT 340

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.